| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sodium Selenite - is inorganic selenium in the selenite oxidation state (Se⁴⁺) Sodium selenite is produced industrially from selenium metal, which itself is obtained as a by-product of copper refining. Mechanistic distinction from Selenium: -Selenite reacts with GSH → GS–Se–SG intermediates -Generates superoxide, H₂O₂ -Exploits cancer cells’ elevated basal oxidative stress -Normal cells neutralize it more effectively (higher redox reserve) Both the uptake and processing of selenium has recently shown to be upregulated in subsets of cancer cells due to their increased expression of xCT transporter The more a tumor depends on xCT, the more toxic selenite becomes. High xCT Also Increases SSE Toxicity. High xCT increases intracellular thiols, which increases SSE chemical trapping, redox cycling, and cytotoxic impact. Sodium selenite might protect against toxicity of AgNPs. also here SSE and cancer
Table to compare Sodium Selenite to SeNPs -Sodium selenite → chemical oxidant (thiol attack → ROS shock). -SeNPs → engineered redox stressor (signaling-level control, broader window). -Selenomethionine / Se-yeast → redox buffer & selenium storage form (often protective to cancer cells, especially when oxidative stress is a therapeutic goal).
|
| Source: |
| Type: |
| The effectiveness of chemotherapy by increasing cancer cell sensitivity to the drugs used to treat them, which is known as “chemo-sensitization”. Chemo-Sensitizers: -Curcumin -Resveratrol -EGCG -Quercetin -Genistein -Berberine -Piperine: alkaloid from black pepper -Ginsenosides: active components of ginseng -Silymarin -Allicin -Lycopene -Ellagic acid -caffeic acid phenethyl ester -flavopiridol -oleandrin -ursolic acid -butein -betulinic acid |
| 5084- | SSE, | GEM, | The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study |
| - | in-vitro, | PC, | PANC1 | - | vitro+vivo, | PC, | Panc02 |
| 5078- | SSE, | Rad, | Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer |
| - | Trial, | Pca, | NA |
| 5073- | SSE, | Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study |
| - | Trial, | Var, | NA |
| 1706- | SSE, | Selenium in Prostate Cancer: Prevention, Progression, and Treatment |
| - | Review, | Pca, | NA |
| 1688- | SSE, | Potential Role of Selenium in the Treatment of Cancer and Viral Infections |
| - | Review, | Var, | NA |
| 4739- | SSE, | Chemo, | Rad, | Therapeutic Benefits of Selenium in Hematological Malignancies |
| - | Review, | Var, | NA |
| 4468- | VitC, | SSE, | Selenium modulates cancer cell response to pharmacologic ascorbate |
| - | in-vivo, | GBM, | U87MG | - | in-vitro, | CRC, | HCT116 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:148 Target#:1106 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid